EGFR and lung adenocarcinoma: It has been previously reported that prostaglandin E2 (PGE2), one of the main mediators of inflammation, can activate Src kinases through EP3 receptors, which in turn transactivate EGFR (regardless of the presence of a ligand) in lung adenocarcinoma cells (78, 79).